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Abstract 
Background: The use of artemisinin as a monotherapy resulted in the emergence of artemisinin resistance in 2005 
in Southeast Asia. Monitoring of artemisinin combination therapy (ACT) is critical in order to detect and prevent the 
spread of resistance in endemic areas. Ex vivo studies and genotyping of molecular markers of resistance can be used 
as part of this routine monitoring strategy. One gene that has been associated in some ACT partner drug resistance is 
the Plasmodium falciparum multidrug resistance protein 1 (pfmdr1) gene. The purpose of this study was to assess the 
drug susceptibility of P. falciparum populations from Thiès, Senegal by ex vivo assay and typing molecular markers of 
resistance to drug components of ACT currently used for treatment.
Methods: The ex vivo susceptibility of 170 P. falciparum isolates to chloroquine, amodiaquine, lumefantrine, artesu-
nate, and artemether was determined using the DAPI ex vivo assay. The high resolution melting technique was used 
to genotype the pfmdr1 gene at codons 86, 184 and 1246.
Results: A significant decrease in IC50 values was observed between 2012 and 2013: from 13.84 to 6.484 for amodi-
aquine, 173.4 to 113.2 for lumefantrine, and 39.72 to 18.29 for chloroquine, respectively. Increase of the wild haplotype 
NYD and the decrease of the mutant haplotype NFD (79 and 62.26 %) was also observed. A correlation was observed 
between the wild type allele Y184 in pfmdr1 and higher IC50 for all drugs, except amodiaquine.
Conclusion: This study has shown an increase in sensitivity over the span of two transmission seasons, marked by 
an increase in the WT alleles at pfmdr1. Continuous the monitoring of the ACT used for treatment of uncomplicated 
malaria will be helpful.
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Background
Among the five species of Plasmodium causing human 
malaria, Plasmodium falciparum is the deadliest. The lat-
est World Malaria Report showed that of the 214 million 
cases of malaria recorded in 2014, 88 % were registered in 
sub-Saharan Africa where most of cases were caused by 
P. falciparum [1, 2].
In the late 1950s, resistance of P. falciparum to 
chloroquine (CQ) emerged in South America and 
Southeast Asia [3]; since then, resistance has spread 
rapidly around the world and in Africa the first cases 
were reported in 1978 [4]. The introduction of other 
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anti-malarial drugs [sulfadoxine-pyrimethamine (SP), 
mefloquine (MQ), etc.] has led to the emergence of 
strains of P. falciparum that are resistant to multiple 
drugs in some endemic areas [5]. As a result, since 
April 2001, the World Health Organization (WHO) 
has recommended the use of artemisinin-based com-
bination therapy (ACT) in countries where P. falcipa-
rum is resistant to CQ, SP, and amodiaquine (AMQ), to 
avoid early emergence of resistance to these molecules 
[6]. Despite these efforts, cases of resistance to arte-
misinin (ART) have emerged in Cambodia and in other 
regions of Southeast Asia [7]. Indeed, in these coun-
tries, ART was used as monotherapy for uncomplicated 
falciparum malaria. Monitoring the sensitivity of P. 
falciparum to ACT becomes essential for therapeutic 
management of malaria. Such monitoring can be done 
by various methods, including in  vivo efficacy studies, 
in vivo clearance time assays [8], in vitro chemo-sensi-
tivity to anti-malarial drugs (RSA), and genotyping of 
pfk13 molecular markers of ART resistance [9]. For the 
P. falciparum multidrug-resistant protein 1 (pfmdr1) 
gene, several single nucleotide polymorphisms were 
described, but the more common were N86Y, Y184F, 
S1034C, N1042D, and D1246Y. Studies have shown an 
association of pfmdr1 gene, specifically the codon 86, 
and a decrease of sensitivity to AMQ and artesunate 
(ARS) [10, 11]. Studies have also shown the 86Y and 
1246Y mutations are strongly related to the reduction 
of in  vivo sensitivity to artesunate-amodiaquine com-
bination (ASAQ). Also, the N86 and D1246 alleles are 
related to a decrease of susceptibility to artemether–
lumefantrine combination (AL) [12–14]. Moreover, 
the haplotype N86F184D1246 is selected by a high 
drug pressure of AL [15, 16], while 1034C, 1042D and 
1246Y mutations have been reported to confer resist-
ance against quinine (QN) and increased susceptibility 
to MQ, halofantrine (HF) and ART [17, 18].
In Senegal, ACT has been implemented as first-line 
treatment for uncomplicated falciparum malaria since 
2006, following WHO recommendation [19]. AL and 
ASAQ combination are used for first-line treatment of 
uncomplicated P. falciparum malaria [2]. Ex vivo studies 
have been conducted to study the sensitivity of current 
anti-malarial drugs used against circulating P. falciparum 
populations in Senegal [20–23]. This work aims to study 
the consequences of use of ACT (ASAQ and AL) for 
uncomplicated malaria treatment in Senegal by using the 
ex vivo sensitivity to ARS, AMQ, artemether (AMT) and 
lumefantrine (LUM) of P. falciparum isolates from Thiès 
collected during the transmission period of malaria com-




Patient recruitment took place during the seasonal 
malaria period (from September to December) in Sec-
tion de Lutte Anti-Parasitaire (SLAP) clinic in Thiès in 
2012 and 2013. This centre has the privilege to control 
malaria treatment in Thiès region. The epidemiological 
profile of this region is characterized as sahelian with a 
short, seasonal transmission period, generally fewer than 
4 months after the rainy season ends. The vectors found 
are Anopheles arabiensis and Anopheles gambiae and the 
entomological inoculation rate is generally low and var-
ies from 1 year to another (0–20 infectious bites/person/
year). The region of Thiès is located at 70 km from Dakar 
and malaria incidence in this region ranges between five 
and 15 per 1000 inhabitants [21, 24].
Individuals who presented at the health centre with 
malaria symptoms were tested by both microscopy and 
rapid diagnostic test (when available). The selected 
patients, aged from 5 to 20  years, had uncomplicated 
malaria due to P. falciparum with a parasitaemia higher 
than 15,000  µl. Exclusion criteria included individuals 
who had clinical features of severe malaria or who had 
a history of taking anti-malarial treatment prior to the 
visit. Informed consent or assent of the patient and their 
guardian (for children) was obtained before collecting the 
blood. The Human Subjects Committee of Tulane Uni-
versity and the Ethics Committee of the Senegal Minis-
try of Health in Dakar both approved the protocols used 
in these studies. The work was supported by the Inter-
national Centres of Excellence for Malaria Research, 
(ICEMR) West Africa (U19AI089696).
Blood sample collection
Venous blood was collected in EDTA tubes and fil-
ter papers were collected by finger prick. Patients were 
treated with AMT-LUM or ARS-AMQ combination. 
These samples were sent to Aristide Le Dantec Hospital 
within 6 h of blood draw.
Drugs and drug preparation
AMQ hydrochloride (USP), ARS (Sigma), AMT 
(SIGMA), CQ diphosphate (Sigma) and LUM (USP) were 
used in ex  vivo assays. These molecules were dissolved 
directly in dimethyl sulfoxide (DMSO) solvent at a con-
centration of 10 mM. A first dilution (1/1000) with RPMI 
1640 media was done to obtain an intermediate solution. 
A serial dilution (1/2) was then operated to get a range of 
concentrations for each drug. The range of concentration 
varied from 100 to 0.39 nM for AMQ, 75 to 0.29 nM for 
ARS, 150 to 0.58 nm for AMT, 750 to 2.93 nM for CQ, 
and 2000 to 7.81  nM for LUM. The 96-well plates were 
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then loaded with drugs at a final volume 20  µl per well 
and stored at −20 °C until use.
Ex vivo assay
Parasitized blood samples from the field were first cen-
trifuged to remove the plasma, then washed two times 
with unsupplemented media. Samples with a parasitae-
mia between 0.4 and 1  % were suspended in complete 
media, supplemented with AB serum and Albumax II to 
adjust the haematocrit to 2  % before being distributed 
into 96-well plates preloaded with drugs. If parasitaemia 
was higher than 1 %, a dilution with an O+ blood sam-
ple without P. falciparum strains was done. The plates 
were incubated at 37  °C under the following gas con-
ditions (1  % O2, 5  % CO2 and 94  % N2) for 48 or 72  h, 
until parasite re-invasion as assessed by microscopy. The 
ex vivo response of parasites to the different anti-malar-
ial drugs was evaluated using the DAPI molecular probe 
as described previously [25]. Plates were briefly thawed, 
spun, and re-suspended with 100  µl (3.64  nM of DAPI 
concentration) of DAPI-buffer and incubated for 30 min 
in the dark. They were washed with the PBS before read-
ing at excitation wavelength of 358  nm and emission 
wavelength of 460 nm using a Fluoroskan Ascent reader. 
Percent growth was calculated relative to the RPMI-only 
control wells for each plate. The control strain used to 
validate results was sensitive to CQ P. falciparum 3D7 
laboratory strain from MR4.
DNA extraction and genotyping
The genomic DNA was extract from filter papers using 
the QIAmp DNA mini kit (Qiagen) following manu-
facturer’s instructions. The high resolution melting 
(HRM) technique was used for genotyping codons N86Y, 
Y184F and D1246Y of pfmdr1 gene and codon K76T of 
pfcrt using specific primers and probes, as previously 
described [26].
Statistical analysis
All statistical analyses were performed using Graph Pad 
Prism software (Version 5.0). Mann–Whitney test was 
used to compare the distribution of IC50 s between years. 
For the difference of pfmdr1 polymorphism, the online Z 
test for two populations’ proportion was used. p value 
was considered significant when it was less than 0.05.
Results
Ex vivo susceptibility of Plasmodium falciparum parasites 
from Thiès
Among a total of 120 and 50 samples collected, respec-
tively, in 2012 and 2013 in Thiès, 114 and 48, respectively, 
were tested. The eight non-tested samples had a parasi-
taemia lower than 15,000 parasites/µl.
Parasites’ responses to drugs at Thiès in 2012 and 
2013 are listed in Table  1. Ex  vivo result was validated 
by testing the 3D7 strain sensitive to CQ and good sen-
sitivity was found with a significant increase. The geo-
metric mean of IC50 values reported in 2012 and 2013 
were, respectively, 13.84 and 6.484  nM (p  <  0.0001) for 
AMQ; 173.4 and 113.2  nM (p  =  0.01) for LUM; 3.322 
and 3.673  nM (p =  0.34) for ARS; 39.72 and 18.29  nM 
(p  <  0.0001) for CQ. AMT was only tested in 2013, the 
geometric mean found was 6.222 nM.
Polymorphism assessment of pfmdr1 and pfcrt genes 
and haplotype of mdr1 gene analysis
The 120 and 50 samples collected in Thiès were success-
fully genotyped. The majority of isolates had the wild 
type alleles N and K at codon 86 (pfmdr1) and 76 (pfcrt) 
with respectively 96 and 78 % in 2012 and 98 and 80 % 
in 2013. Mixed allele was found in 2012 in 1 % for N86Y 
and 2  % for K76T of proportion. The mutant allele for 
these codons was in proportion of 3 and 2 % in 2012 and 
2 and 0 % in 2013. Concerning the 184 codon, the mutant 
allele F predominates both in the 2 years with 75 % for F 
Table 1 Ex vivo susceptibility of Plasmodium falciparum isolates from Thiès in 2012 and 2013
The chloroquine-sensitive strain 3D7 was tested and gave adequate results <100 nM [44]. The difference of values for each molecule for 3D7 was significant excepted 
for artesunate (p = 0.35). p value indicates the significance of the difference of geometric means of the same molecule between 2012 and 2013
IC50 50 % inhibitory concentration, IC confidence interval, Mean geometric mean, min minimum, max maximum
Drug 2012 2013 p value
3D7 IC50 
(nM)
Mean with 95 % IC 
(nM)
Range (nM) 3D7 IC50 
(nM)
Mean with 95 % IC 
(nM)
Range (nM)
Min Max Min Max
AMQ 5.488 13.84 (11.84–16.13) 0.7425 63.13 3.321 6.484 (5.208–8.071) 1.925 43.85 <0.0001
LUM 417.5 173.4 (142.0–211.8) 21.26 981.1 164.3 113.2 (85.9–149.1) 17.05 414 0.01
ARS 17.88 3.322 (2.852–3.869) 0.5222 10.16 2.805 3.673 (3.046–4.428) 1.22 18.54 0.34
AMT – – – 7 6.222 (5.013–7.724) 1.188 33.6 –
CQ 17.58 39.72 (30.92–51.02) 2.850 402.9 9.287 18.29 (29.07–87.59) 6.474 384.1 <0.0001
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allele (vs. 20 % for Y allele) in 2012 and 60 % for F allele 
(vs. 34 % for Y allele) in 2013 with a significant difference 
(p = 0.029). The presence of mixed allele in Thiès isolates 
(3 % in 2012 and 6 % in 2013) for this codon was noted. 
Finally, for 1246 codon, the only allele found was the wild 
type D1246 (Table 2).
Samples containing single allele in the codons N86Y 
and Y184F were used to determine prevalence of the cir-
culating pfmdr1 to reduce ambiguity from the mixed sam-
ples. The haplotypes N86Y184D1246, N86F184D1246 
and Y86F184D1246 were found both in 2012 and 2013 
(Table 2). A high prevalence of N86F184D1246 haplotype 
was found 79 % in 2012 and 62.26 % in 2013 with a sig-
nificant decrease in 2013.
Both the wildtype Y184 and the combined N86Y184D1246 
are selected in 2013.
Genotype and phenotype analysis
An association analysis between 184F mutation and the 
ex vivo susceptibility to LUM, AMT, CQ, AMQ, and ARS 
was performed (Table 3). High geometric means of IC50 
for LUM were found with samples having the wild allele 
Y184 in 2012 isolates (p =  0.0008). For the other com-
pounds, no difference between the geometric mean of 
IC50 of isolates with the 184F allele and that of GM of 
IC50 s with the wild allele was see.
Discussion
Plasmodium falciparum resistance exists to all first-line 
anti-malarial drugs, used in both the past and present, 
alarmingly, even artemisinin derivatives. This resist-
ance has been confirmed in five countries in Southeast 
Asia (Cambodia, The Lao People’s Democratic Republic, 
Myanmar, Thailand, Viet Nam) [27]. Monitoring ACT 
resistance worldwide is absolutely essential, as there is no 
other alternative drug treatment available [28].
In Senegal, ACT has been first-line treatment since 
2006, and currently, AL and ASAQ are recommended as 
first-line treatment of uncomplicated malaria, while dihy-
droartemisinin-piperaquine is used as second-line [2, 19]. 
Both combinations (AL and ASAQ) are effective event 
for child and adult [29]. However, AL is used more fre-
quently because it is better tolerated [30]. ACT treatment 
failure of 0.9 % for AL was observed between 2004 and 
2014 and it was 0.25 % for ASAQ treatment [2]. Previous 
studies showed that AL, DHAPQ and ASAQ are highly 
effective for the treatment of uncomplicated P. falcipa-
rum malaria in Senegal [31, 32]. In Thiès (2012–2013) 
three recrudescent samples were observed and these did 
not reveal mutation in the K13 propeller region (Dieye 
et al. pers. comm.).
The DAPI ex  vivo test, that has been shown to be an 
excellent technique to study the chemo-sensitivity of P. 
falciparum [20, 25], was used to measure the ex vivo sen-
sitivity of isolates from Thiès in 2012 and 2013 to AMQ, 
CQ, LUM, ARS, and AMT. Currently, novel phenotype 
assays (RSA) and a new molecular maker of mutations in 
the kelch 13 (K13) propeller region [9], to detect resist-
ance of ART derivatives, are used and recommended 
[33–35]. However, in this study, the data presented was 
manipulated in the seasonal period of 2012 and 2013, 
before the RSA recommendation in December 2013. 
Kelch 13 sequencing was performed and no mutations 
known to confer resistance were observed in these sam-
ples (Deme & Ndiaye, pers. comm).
To validate the result, 3D7 chloroquine sensitive strain 
was used. Good sensitivity (<00 nM) was found for chlo-
roquine in both years. A significant increase of sensitivity 
Table 2 Prevalence of  single nucleotide polymorphism et 
haplotypes of pfmdr1 gene of isolates from Thiès
pfmdr1 genotype 2012 (120) 2013 (N = 50) p value
N86 97 % (84/87) 98 % (49/50) 0.63
86Y 2 % (2/87) 2 % (1/50) 0.1151
MIXTE (N86Y) 1 % (1/87) 0 % 0.44
Y184 20 % (22/119) 34 % (17/50) 0.029
184F 78 % (93/119) 60 % (30/50) 0.0155
MIXTE (Y184F) 3 % (4/119) 6 % (3/50) 0.42
D1246 100 % (119/119) 100 % (50/50) –
K76 78 % (47/60) 80 % (40/50) 0.83
76T 20 % (12/60) 20 % (10/50) 1
MIXTE 2 % (1/60) 0 % 0.36
NYD 18 % (18/102) 35.85 % (18/50) 0.012
NFD 79 % (81/102) 62.26 % (31/50) 0.022
YFD 3 % (3/102) 1.89 % (1/50) 0.72
Table 3 Association between  the mutation 184F and  the 
geometric means of IC50 values for each drugs
The numbers in parentheses indicate the number of samples with wild or 
mutant allele
Drugs Year IC50 geometric mean (nM)
Y184 184F p value
Amodiaquine 2012 10.51 (19) 15.02 (69) 0.0671
2013 5.1 (16) 6.277 (24) 0.1992
Chloroquine 2012 117.8 (20) 104 (89) 0.1094
2013 24.18 (15) 28.10 (27) 0.1036
Lumefantrine 2012 493.6 (15) 179.2 (69) 0.0008
2013 155.9 (15) 68.13 (23) 0.1277
Artesunate 2012 4.034 (12) 3.041 (60) 0.3808
2013 3.365 (17) 3.693 (25) 0.5729
Artemether 2012 – – –
2013 5.997 (17) 5.936 (25) 0.9387
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was observed for 3D7 and isolate from Thiès and this, for 
all molecules except artesunate, which means the differ-
ences in drugs between years could be for technical rea-
sons rather than biological ones. ARS and AMT exert 
their actions through formation of dihydroartemisinin 
in  vivo [36]. This metabolite is often present in higher 
concentrations than the parent drugs. However, stud-
ies show that AMT and ARS have potent parasite kill-
ing activity in vitro [37]. This id why AMT and ARS were 
tested separately.
Also, five single nucleotide polymorphisms in the 
pfmdr1 gene were associated to anti-malarial drug resist-
ance. Studies show that the pfmdr1 gene polymorphism 
at codons N86Y, Y184F and D1246Y is mainly linked to 
AL or ASAQ drug pressure [15, 38, 39]. These facts jus-
tify the choice of the three codons of pfmdr1 gene.
The resistance to AMQ has always been linked to the 
mutation at the 86 position of the pfmdr1 gene [10, 11]. 
Studies show that high ASAQ pressure on the para-
site population can select Y86Y184Y1246 haplotypes 
[15]. The existence of cross resistance, strains resist-
ance to both of drugs together, between AMQ and CQ 
was detected [40]. The result obtained in Thiès, com-
bined with those obtained in the same region in 2010 
[25] and in 2013 [20] reveal that the ex vivo sensitivity of 
the parasite population to AMQ and CQ has increased 
between 2011 and 2013. Also, as previously described in 
Thiès [20], a decrease of the mutation at the 86 position 
was observed. Studies show that the prevalence of 86Y 
allele increased between 2000 and 2003 on parasites from 
Pikine (Dakar). However, a decrease was noted between 
2003 and 2009 in this locality [41]. These results reveal 
that sensitivity of parasite to AMQ increased drastically 
after the abandonment of chloroquine in 2003. The same 
tendency was observed in Thiès. Also, for the Pfmdr1 
gene, the haplotype Y86Y184Y1246 was not found. This 
means that the drugs ARS and AMQ are effective on 
the population of P. falciparum from Thiès and any drug 
pressure was noted. Increase of wild-type allele K76 was 
also found between 2011 and 2013 in Thiès. The study of 
Ndiaye et  al. [42] also showed this increase in the cen-
tral (70.5 % in 2009 and 74.8 % in 2010) and in southern 
(65.4 % in 2010 and 71.0 % in 2011) Senegal.
The combination AMT-LUM has been used as first-
line treatment for uncomplicated malaria in Senegal 
since 2006 [43]. The resistance to LUM has been linked 
to the increase of copy number in the pfmdr1 gene and 
the selection of the N86 allele [10]. However, studies have 
shown a selection of the N86F184D1246 haplotype by a 
high pressure of AL [12, 16]. The high prevalence of wild 
allele N86, mutant allele 184F and N86F184D1246 hap-
lotype was also noted in this study. In Thiès, Van Tyne 
et  al. [20] demonstrated an increase of the 184F muta-
tion between 2008 and 2011. However, a tendency to a 
decrease of this mutation between 2011 and 2013 was 
noted. This tendency can be explained by the use of 
the ASAQ combination in SLAP (health centre) after 
the unavailability of AL. This observation means that a 
pressure is exerted by AMT-LUM combination on the 
parasite population from Thiès and then this pressure 
decreases if the drug (AL) is not used.
Conclusion
The study of ex vivo sensitivity of P. falciparum to anti-
malarial drugs is a powerful tool to understand parasite 
phenotypes and to orient the policy of monitoring thera-
peutic management of malaria. The results of this study 
show a good sensitivity of P. falciparum populations to 
amodiaquine, artesunate, artemether and lumefantrine. 
So, the high prevalence of N86F184D1246 haplotype 
selected by AL pressure was found. Expanded in  vivo 
surveillance of ACT and continued monitoring of arte-
misinin drug resistance by using new techniques, such 
as the ex vivo RSA and kelch13 genotyping, should be a 
priority.
Authors’ contributions
AM, BD, YDN, ABD, MSY, AG, IMN, TN, ASB, MAD, MN, MCS, MA and AKB carried 
out the experiments and collected data. NS, DN, DJK, OK, DN conceived and 
designed the study. AM and AKB analysed the data. AM, BD, KD, ABD and YDN 
wrote the manuscript. All authors read and approved the final manuscript.
Author details
1 Laboratory of Parasitology/Mycology HALD, Cheikh Anta Diop Univer-
sity of Dakar, PO Box 5005, Dakar, Senegal. 2 Department of Immunology 
and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA. 
3 Tulane University, New Orleans, LA, USA. 4 Malaria Research Centre, Ser-
rekunda, Gambia. 5 University of Bamako, Bamako, Mali. 
Acknowledgements
We acknowledge the International Center for Excellence in Malaria Research 
(ICEMR) project. We thank Cyrille Diedhiou, Nasserdine Papa Nze, Dior Diop, 
Younouss Diedhiou, Lamine Ndiaye, Amadou Mactar Mbaye, the SLAP patients 
and staff for their contribution in this study.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
The participants in this study are consent for publication.
Ethics approval and consent to participate
The Human Subjects Committee of Tulane University and the Ethics Commit-
tee of the Senegal Ministry of Health in Dakar both approved the protocols 
used in these studies.
Funding
The work was supported by the International Centers of Excellence for Malaria 
Research, (ICEMR) West Africa (U19AI089696).
Received: 9 June 2016   Accepted: 16 August 2016
Page 6 of 7Mbaye et al. Malar J  (2016) 15:433 
References
 1. WHO. Q&A on artemisinin resistance. Geneva, World Health Organization. 
2013 http://who.int/malaria/media/artemisinin_resistance_qa/en/.
 2. WHO. World Malaria Report. Geneva, World Health Organization. 2015. 
http://apps.who.int/iris/bitstream/10665/200018/1/9789241565158_eng.
pdf.
 3. Blount RE. Management of chloroquine resistant falciparum malaria. 
Trans Am Clin Climatol Assoc. 1967;78:196–204.
 4. Kihamia CM, Gill HS. Chloroquine-resistant falciparum malaria in semi-
immune native African Tanzanians. Lancet. 1982;2:43.
 5. Anderson TJ, Roper C. The origins and spread of antimalarial drug resist-
ance: lessons for policy makers. Acta Trop. 2005;94:269–80.
 6. WHO. Briefing on malaria treatment guidelines and artemisinin mono-
therapies. Geneva, World Health Organization. 2006. http://apps.who.int/
malaria/docs/Meeting_briefing19April.pdf.
 7. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence 
of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 
2008;359:2619–20.
 8. WHO. Global report on antimalarial drug efficacy and drug resistance: 
2000–2010. Geneva: World Health Organization; 2010.
 9. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. 
Molecular marker of artemisinin-resistant Plasmodium falciparum malaria. 
Nature. 2014;505:50–5.
 10. Pradines B, Dormoi J, Briolant S, Bogreau H, Rogier C. La résistance aux 
antipaludiques. Revue Francophone des Laboratoires. 2010; 422.
 11. Eyase FL, Akala HM, Ingasia L, Cheruiyot A, Omondi A, Okudo C, et al. The 
role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, meflo-
quine and lumefantrine susceptibility in Western-Kenya P. falciparum 
samples during 2008–2011. PLoS One. 2013;8:e64299.
 12. Kavishe RA, Paulo P, Kaaya RD, Kalinga A, Van Zwetselaar M, Chilongola J, 
et al. Surveillance of artemether-lumefantrine associated Plasmodium fal-
ciparum multidrug resistance protein-1 gene polymorphisms in Tanzania. 
Malar J. 2014;13:264.
 13. Ashley E, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, 
et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. 
N Engl J Med. 2014;371:411–23.
 14. Sisowath C, Petersen I, Veiga MI, Mårtensson A, Björkman A, Fidock DA, 
Gil JP. In vivo selection of Plasmodium falciparum parasites carrying the 
chloroquine-susceptible pfcrt K76 allele after treatment with artemether–
lumefantrine in Africa. J Infect Dis. 2009;199:750–7.
 15. Baliraine FN, Rosenthal PJ. Prolonged selection of pfmdr1 polymorphisms 
after treatment of falciparum malaria with artemether-lumefantrine in 
Uganda. J Infect Dis. 2011;204:1120–4.
 16. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O’Neil M, 
et al. Selection of Plasmodium falciparum multidrug resistance gene 1 
alleles in asexual stages and gametocytes by artemether–lumefantrine 
in Nigerian children with uncomplicated falciparum malaria. Antimicrob 
Agents Chemother. 2009;53:888–95.
 17. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJM, Mutabingwa TK, 
Sutherland CJ, et al. Amodiaquine and artemether–lumefantrine select 
distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian 
children treated for uncomplicated malaria. Antimicrob Agents Chem-
other. 2007;51:991–7.
 18. Jacqueline K, Lekostaj L, Amoah E, Roepe PD. A single S1034C mutation 
confers altered drug sensitivity to PfMDR1 ATPase activity that is charac-
teristic of the 7G8 isoform. Mol Biochem Parasitol. 2008;157:107–11.
 19. PNLP. Directives nationales de prevention et de prise en charge du 
paludisme. Dakar. 2013-24. http://www.asgosenegal.org/docs/Direc-
tivesPECVFF.pdf.
 20. Van Tyne D, Dieye B, Valim C, Daniels RF, Sène PD, Lukens AK, et al. 
Changes in drug sensitivity and anti-malarial drug resistance mutations 
over time among Plasmodium falciparum parasites in Senegal. Malar J. 
2013;12:441.
 21. Ndiaye D, Dieye B, Ndiaye YD, Tyne DV, Daniels R, Bei AK, et al. Poly-
morphism in dhfr/dhps genes, parasite density and ex vivo response 
to pyrimethamine in Plasmodium falciparum malaria parasites in Thies, 
Senegal. Int J Parasitol Drugs Drug Resist. 2013;3:135–42.
 22. Fall B, Camara C, Fall M, Nakoulima A, Dionne P, Diatta B, et al. Plasmodium 
falciparum susceptibility to standard and potential anti-malarial drugs in 
Dakar, Senegal, during the 2013–2014 malaria season. Malar J. 2015;14:60.
 23. PNLP. Plan Stratégique National 2011–2015. Dakar. 2010-129. 
http://www.africanchildforum.org/clr/policypercountry/senegal/
senegal_malaria_2011-2015_fr.pdf.
 24. PNLP. Bulletin épidémiologique annuel du paludisme au Senegal. Dakar. 
2014-24. http://www.pnlp.sn/telechargements/Rapports/Bulletin-Epide-
miologique-Annuel-2014-du-Paludisme-au-Senegal.pdf.
 25. Ndiaye D, Patel V, Demas A, LeRoux M, Ndir O, Mboup S, et al. A non-radi-
oactive DAPI-based high-throughput in vitro assay to assess Plasmodium 
falciparum responsiveness to antimalarials—increased sensitivity of P. fal-
ciparum to chloroquine in Senegal. Am J Trop Med Hyg. 2010;82:228–30.
 26. Daniels R, Ndiaye D, Wall M, McKinney J, Séne PD, Sabeti PC, et al. Rapid, 
field-deployable method for genotyping and discovery of single-nucle-
otide polymorphisms associated with drug resistance in Plasmodium 
falciparum. Antimicrob Agents Chemother. 2012;56:2976–86.
 27. WHO. Status report on artemisinin resistance. Geneva: World Health 
Organization; 2014.
 28. Ménard D, Ariey F, Mercereau-Puijalon O. Étude de la résistance de Plas-
modium falciparum aux antipaludiques au sein du réseau international 
des Instituts Pasteur. Med Sci (Paris). 2013;29:647–55.
 29. Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, 
et al. Randomized, multicentre assessment of the efficacy and safety of 
ASAQ–a fixed-dose artesunate-amodiaquine combination therapy in 
the treatment of uncomplicated Plasmodium falciparum malaria. Malar J. 
2009;8:125.
 30. Maiteki-Sebuguzi C, Jagannathan P, Yau VM, Clark TD, Njama-Meya 
D, et al. Safety and tolerability of combination antimalarial therapies 
for uncomplicated falciparum malaria in Ugandan children. Malar J. 
2008;7:106.
 31. Sylla K, Abiola A, Tine R, Faye B, Sow D, Ndiaye JL, et al. Monitoring the 
efficacy and safety of three artemisinin-based combinations thera-
pies in Senegal: Results from two years surveillance. BMC Infect Dis. 
2013;13:598.
 32. Faye B, Offianan AT, Ndiaye JL, Tine RC, Touré W, Djoman K, et al. Efficacy 
and tolerability of artesunate-amodiaquine (Camoquin plus) versus 
artemether-lumefantrine (Coartem) against uncomplicated Plasmodium 
falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop Med Int 
Health. 2010;15:608–13.
 33. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel 
phenotypic assays for the detection of artemisinin-resistant Plasmodium 
falciparum malaria in Cambodia: in vitro and ex vivo drug-response stud-
ies. Lancet Infect Dis. 2013;13:1043–9.
 34. Fandeur T. Laboratoire National de Référence pour la surveillance des 
Chimiorésistances du Paludisme au Niger. 2011; 1–19.
 35. Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, et al. Reduced arte-
misinin susceptibility of Plasmodium falciparum ring stages in Western 
Cambodia. Antimicrob Agents Chemother. 2013;57:914–23.
 36. Brewer TG, Grate SJ, Peggins JO, Weina PJ, Petras JM, Levine BS, et al. 
Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg. 
1994;51:251–9.
 37. Huang X, Aslanian RG. Case studies in modern drug discovery and devel-
opment. London: Wiley; 2012.
 38. Achieng AO, Muiruri P, Ingasia LA, Opot BH, Juma DW, Yeda R, et al. Tem-
poral trends in prevalence of Plasmodium falciparum molecular markers 
selected for by artemether-lumefantrine treatment in pre-ACT and 
post-ACT parasites in Western Kenya. Int J Parasitol Drugs Drug Resist. 
2015;5:92–9.
 39. Sisowath C, Ferreira PE, Bustamante LY, Dahlström S, Mårtensson 
A, Björkman A, et al. The role of pfmdr1 in Plasmodium falciparum 
tolerance to artemether-lumefantrine in Africa. Trop Med Int Health. 
2007;12:736–42.
 40. Trape JF, Tall A, Sokhna C, Ly AB, Diagne N, Ndiath O, et al. The rise and 
fall of malaria in a West African rural community, Dielmo, Senegal, 
from 1990 to 2012: a 22 year longitudinal study. Lancet Infect Dis. 
2014;14:476–88.
 41. Ly O, Gueye PE, Deme AB, Dieng T, Badiane AS, Ahouidi AD, et al. 
Evolution of the pfcrt T76 and pfmdr1 Y86 markers and chloroquine 
susceptibility 8 years after cessation of chloroquine use in Pikine, Senegal. 
Parasitol Res. 2012;111:1541–6.
 42. Ndiaye M, Faye B, Tine R, Ndiaye JL, Lo A, Abiola A, et al. Assessment of 
the molecular marker of Plasmodium falciparum chloroquine resistance 
Page 7 of 7Mbaye et al. Malar J  (2016) 15:433 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
(Pfcrt) in Senegal after several years of chloroquine withdrawal. Am J Trop 
Med Hyg. 2012;87:640–5.
 43. Mouzin E, Thior PM, Diouf MB, Samb B. Focus sur le Senegal. Geneva, Roll 
Back Malaria. 2010. http://www.rollbackmalaria.org/files/files/resources/
report4-fr.pdf.
 44. Pradines B, Tall A, Parzy D, Spiegel A, Fusai T, Hienne R, et al. In-vitro activ-
ity of pyronaridine and amodiaquine against African isolates (Senegal) of 
Plasmodium falciparum in comparison with standard antimalarial agents. 
J Antimicrob Chemother. 1998;42:333–9.
